November 23, 2010 Amorfix Announces Success in Generating High Affinity Antibodies to Cancer Specific Epitopes
October 21, 2010 Amorfix Life Sciences and Biotrofix Announces Detection of Aggregated Beta-Amyloid in CSF Using the A4 Alzheimer's Test
October 20, 2010 Amorfix Life Sciences Appoints Dr. Walter Von Wartburg to Board of Directors and Enhances Business Development Activities
October 7, 2010 Amorfix Life Sciences Announces Membership in Alzheimer's Disease Neuroimaging Initiative (ADNI)
September 16, 2010 Amorfix Life Sciences Announces Publication of A4 Data in Prestigious Journal of Alzheimer's Disease and Provides Update on Management Changes
August 16, 2010 Early Warning Report Issued Pursuant to National Instrument 62-103 Acquisition of Shares of Amorfix Life Sciences
August 12, 2010 Amorfix Announces First Quarter Fiscal 2011 Results
July 22, 2010 Conference Call to Review Recent Business Development Activities and Near-Term Company Goals
July 14, 2010 Amorfix Life Sciences Announces Global Licensing Agreement For The Treatment of ALS with Biogen Idec
July 12, 2010 Amorfix A4 Assay Provides New Insights Into Alzheimer's Disease Pre-Clinical Development Mouse Models
July 6, 2010 Amorfix and reMYND announces testing service agreement for the A4 Alzheimer's Test
June 24, 2010 Amorfix and QED Bioscience announce agreement to develop novel monoclonal antibodies for cancer
June 3, 2010 Amorfix Life Sciences and Prevent announce global licensing agreement for the treatment of ALS
June 2, 2010 Amorfix announces management change and product development plans for fiscal 2011
May 31, 2010 Corporate update on vCJD test development
May 28, 2010 Amorfix and Aragen Bioscience enter into agreement to develop novel monoclonal antibodies for the treatment of cancers
May 11, 2010 Amorfix and Epitomics enter into agreement to develop novel monoclonal antibodies against disease specific epitopes for the treatment of cancerst
May 4, 2010 Amorfix Life Sciences announces world's first detection of aggregated beta-amyloid in blood using the Alzheimer's diagnostic A4 Assay
February 8, 2010 Amorfix announces third quarter 2010 results
January 6, 2010 Biopharmaceutical executive, Dr. Robert Gundel, joins Amorfix as vice president, research & development